Januvia®
Sitagliptin is a DPP-4 inhibitor for type 2 diabetes. It increases active incretin levels, stimulating insulin release and reducing glucagon in a glucose-dependent manner.
| Dosage Form | Oral Tablet (Film-Coated) |
| Strength | 25 mg, 50 mg, 100 mg |
| Storage | Store at 20–25°C. |
| Category | Diabetes & GLP-1 |
| Availability | Available for Transfer |
Type 2 diabetes mellitus (adjunct to diet and exercise, as monotherapy or in combination with metformin, sulfonylureas, or insulin).
Selectively inhibits dipeptidyl peptidase-4 (DPP-4), preventing the degradation of incretin hormones GLP-1 and GIP. This increases insulin secretion and decreases glucagon in a glucose-dependent manner.
Each Burrard Pharmaceuticals technology transfer package for Sitagliptin includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier templates — available through Burrard Intelligence subscription.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Our team can deliver the complete know-how package within 2–21 business days. Book a consultation to discuss your specific requirements.